# OnCo record tyk-medicines (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/tyk-medicines/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "tyk-medicines" ;
  schema:name "TYK Medicines"@en ;
  schema:alternateName "Zhejiang Tongyuankang Pharmaceutical"@en, "同源康医药"@en ;
  schema:description "TYK Medicines is a China-based biotechnology company that leads 3 cancer trials in OnCo, testing the EGFR inhibitor asandeutertinib (TY-9591) and TYK-00540 in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and brain and spinal cord tumours."@en ;
  schema:url <https://onco.cc/companies/tyk-medicines/>, <https://www.tykmedicines.com> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://www.tykmedicines.com>, <https://clinicaltrials.gov/search?lead=TYK%20Medicines%2C%20Inc> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/brain-tumours/> ;
  onco:drugs <https://onco.cc/drugs/ty-9591/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:trials <https://onco.cc/trials/fleteo/>, <https://onco.cc/trials/nct06950086/>, <https://onco.cc/trials/nct05948813/> .